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BACKGROUND AND PURPOSE
Many GPCRs, including the CB1 cannabinoid receptor, are down-regulated following prolonged agonist exposure by
interacting with the GPCR-associated sorting protein-1 (GASP-1). The CB1 receptor antagonist rimonabant has also recently
been described to be an agonist at GPR55, a cannabinoid-related receptor. Here we investigated the post-endocytic properties
of GPR55 after agonist exposure and tested whether GASP-1 is involved in this process.
EXPERIMENTAL APPROACH
We evaluated the direct protein-protein interaction of GPR55 with GASP-1 using (i) GST-binding assays and (ii)
co-immunoprecipitation assays in GPR55-HEK293 cells with endogenous GASP-1 expression. We further tested the
internalization, recycling and degradation of GPR55 using confocal fluorescence microscopy and biotinylation assays in the
presence and absence of GASP-1 (lentiviral small hairpin RNA knockdown of GASP-1) under prolonged agonist [rimonabant
(RIM), lysophosphatidylinositol (LPI)] stimulation.
KEY RESULTS
We showed that the prolonged activation of GPR55 with rimonabant or LPI down-regulates GPR55 via GASP-1. GASP-1 binds
to GPR55 in vitro, and this interaction was required for targeting GPR55 for degradation. Disrupting the GPR55-GASP-1
interaction prevented post-endocytic receptor degradation, and thereby allowed receptor recycling.
CONCLUSION AND IMPLICATIONS
These data implicate GASP-1 as an important regulator of ligand-mediated down-regulation of GPR55. By identifying GASP-1
as a key regulator of the trafficking and, by extension, functional expression of GPR55, we may be one step closer to gaining
a better understanding of this receptor in response to cannabinoid drugs.
LINKED ARTICLES
This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section
visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit
http://dx.doi.org/10.1111/bph.2011.163.issue-7
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Introduction
The endocannabinoid system consists of endogenous can-
nabinoids, two well-defined seven transmembrane spanning/
GPCRs (7TM/GPCRs), the cannabinoid 1 (CB1) and
cannabinoid 2 (CB2) receptors (Pertwee, 1997), as well as
enzymes synthesizing and degrading endocannabinoids.
The recently de-orphanized GPCR 55 (GPR55) has been
implicated as a novel cannabinoid receptor, since besides
being activated by the endogenous lipid ligand L-a-
lysophosphatidylinositol (LPI), several synthetic CB1 inverse
agonists/antagonists, such as AM251, AM281 and rimona-
bant (SR141716A, RIM), have been shown to activate this
receptor (Oka et al., 2007; Ryberg et al., 2007; Henstridge
et al., 2009; 2010; Kapur et al., 2009; Yin et al., 2009; Brown
et al., 2011). Rimonabant (Acomplia ®, Sanofi-Aventis) has
further attracted attention since it was marketed to induce
weight loss and reduce smoking. However, due to severe side
effects, such as the development of anxiety and depression,
rimonabant was withdrawn from the market (Christensen
et al., 2007).
Depending on the cellular background, activated GPR55
has been shown to couple to a variety of G-proteins (Ryberg
et al., 2007; Lauckner et al., 2008; Schroder et al., 2010; Sharir
&Abood, 2010) and to activate signal cascades involving small
GTPases, oscillatory Ca2+-release, MAP kinases and a variety of
transcription factors (Henstridge et al., 2009; 2010; Balenga
et al., 2011a). However, the pharmacology and signalling
properties of this receptor remain controversial (Pertwee et al.,
2010). Accumulating evidence suggests that GPR55 plays a
role in diverse physiological systems (Balenga et al., 2011b),
including cancer development (Ford et al., 2010; Andradas
et al., 2011; Pineiro et al., 2011), bone formation (Whyte et al.,
2009), pain regulation and inflammation (Staton et al., 2008;
Pietr et al., 2009; Balenga et al., 2011a). For instance, it has
been reported that GPR55 is highly expressed in malignant
human tumours (Andradas et al., 2011) and cancer cell lines
(Ford et al., 2010; Pineiro et al., 2011), and its expression level
is directly correlated to the aggressiveness of the tumours
(Andradas et al., 2011). Likewise, GPR55 was shown to be
expressed in human osteoclasts, and its activation to stimulate
osteoclast polarization and resorption in vitro (Whyte et al.,
2009). In addition, GPR55–/–mice have been shown to be
resistant to inflammatory and neuropathic pain (Staton et al.,
2008), andGPR55may play a role in inflammatory response of
microglial cells (Pietr et al., 2009).
GPCR-mediated signalling is extensively regulated to
guarantee an appropriate cell surface receptor density in a
given physiological setting. One of these regulatory mecha-
nisms is that of receptor endocytosis. Many GPCRs are
endocytosed by a mechanism involving receptor phosphory-
lation, interaction with b-arrestins and concentration in
clathrin-coated pits (Ferguson et al., 1998). However, the
functional consequences of GPCR endocytosis through this
conserved cellular mechanism are diverse. Trafficking of
internalized GPCRs by a rapid recycling pathway restores the
complement of functional receptors in the plasma membrane
and promotes resensitization of receptor-mediated signal
transduction. In contrast, the sorting of internalized GPCRs
to lysosomes promotes proteolytic down-regulation of recep-
tors, leading to a prolonged attenuation of cellular signal
transduction (Tsao et al., 2001). Several proteins have recently
been identified that specifically target GPCRs – typically by
interaction with their C-terminal domains – to either recy-
cling or degradative pathways (Hanyaloglu and von Zastrow,
2008). One such protein is the GPCR-associated sorting
protein 1 (GASP-1) (Whistler et al., 2002).
GASP-1 was originally found to target d-opioid receptors
(DOP) to lysosomes and hence a degradative pathway (Whis-
tler et al., 2002). GASP-1 has since been shown to interact
with the carboxyl-termini of many GPCRs (Heydorn et al.,
2004) and to regulate the trafficking properties of many of
these, both in vitro and in vivo (bu-Helo and Simonin, 2010;
Moser et al., 2010). For instance, experiments examining the
function of the dopamine D2 receptor both in vitro and in vivo
revealed that GASP-1 plays a crucial role in regulating agonist
responses via this receptor (Bartlett et al., 2005; Boeuf et al.,
2009; Thompson et al., 2010). When slices from the rat
ventral tegmental area (VTA) were pretreated with the D2
receptor agonist quinpirole, the receptors failed to recover
from desensitization, which was consistent with the ability of
the D2 receptor to degrade after endocytosis. However, dis-
rupting the D2 receptor /GASP-1 interaction with an inhibi-
tory antibody allowed recovery of functional D2 receptor
responses (Bartlett et al., 2005). Along these lines, repeated
treatment of wild-type – but not GASP-1 knockout – mice
with cocaine lead to a down-regulation of D2 receptors in
mouse striatum (Thompson et al., 2010). In addition, GASP-1
knockout mice showed reduced locomotor sensitization to
cocaine (Thompson et al., 2010) and reduced acquisition of
cocaine self-administration (Boeuf et al., 2009).
In addition, we have previously reported that the CB1
receptor is targeted to lysosomes and the degradative
pathway via GASP-1 after prolonged stimulation with the
agonist WIN55,212–2 in vitro (Martini et al., 2007). This CB1/
GASP-1 interaction has important physiological conse-
quences; i.e. the down-regulation of CB1 receptors via GASP-1
is a key determinant in the development of analgesic toler-
ance to cannabinoid drugs in vivo (Tappe-Theodor et al., 2007;
Martini et al., 2010). Importantly, GASP-1 was recently found
to be a crucial determent in directly regulating not only the
trafficking but also the signalling capacity of a GPCR (e.g. the
viral receptor US28) (Tschische et al., 2010).
Little is known regarding the internalization and post-
endocytic trafficking properties of GPR55. Without ligand
stimulation, GPR55 is predominantly located on the cell
surface and internalizes following agonist stimulation in dif-
ferent cell models, such as HEK293, U2OS and MCF-7 cells
(Henstridge et al., 2009; 2010; Kapur et al., 2009; Ford et al.,
2010). Here we characterize the internalization and post-
endocytic sorting properties of GPR55 after stimulation with
the cannabinoid drug rimonabant as well as the endogenous
ligand LPI and demonstrate that GASP-1 is crucially involved
in regulating the trafficking of GPR55.
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Methods
DNA constructs
The human GPR55 (nomenclature follows Alexander et al.,
2011) was tagged on the N-terminus with the FLAG epitope
(DYKDDDDA) and inserted into a pcDNA3.1(+)vector. The
cloning of the FLAG-d-opioid and FLAG-m-opioid receptors
was previously described inWhistler et al. (2002). The GPR55-
GST-fusion protein was constructed by subcloning the last 34
carboxyl-terminal amino acids of the human GPR55 into the
pGEX-4T-1 plasmid. The generation of the GST-fusion protein
constructs of the delta-opioid-receptor (DOP), the m-opioid
receptor (MOP) and the HA-tagged GASP-1 construct (HA-
GASP-1) were as previously described (Whistler et al., 2002).
The generation of the lentivirus constructs encoding small
hairpin RNA (shRNA) against GASP-1 (shGASP-1) or scrambled
shRNA (shScr) are described in Tschische et al. (2010). All DNA
constructs were verified by sequencing.
Cell culture and stable cell lines
HEK293 cells were cultured in Dulbecco’s modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) at 37°C in 5% CO2, humidified atmosphere. HEK293
cells stably expressing the human FLAG-GPR55 (GPR55-HEK)
were generated by selection with zeocin containing medium.
GPR55-HEK cells were deprived of serum overnight in Opti-
MEM before all experiments.
Co-immunoprecipitation
FLAG-GPR55 was co-immunoprecipitated with endogenous
GASP-1 as previously described (Whistler et al., 2002). Briefly,
HEK293 cells were transiently transfected with FLAG-GPR55
using Lipofectamine 2000, and 48 h post-transfection experi-
ments were performed. Cells were washed twice with ice-cold
PBS and lysed in IPB buffer (0.3% Triton X-100, 150 mM
NaCl, 25 mM KCl, 1 mM CaCl2, 10 mM Tris–HCl, pH 7.4,
supplemented with complete protease inhibitors). Lysates
were centrifuged, and supernatant was incubated with 20 mL
of anti-FLAG M2 monoclonal antibody affinity matrix over
night at 4°C. 30 mL of lysates were kept for FLAG, GASP and
b-actin control blots. Precipitates were washed, deglycosy-
lated with PNGase, resolved by SDS-PAGE and transferred to
a PVDF membrane. Membranes were blocked, probed with
either anti-FLAG M2 antibody (1:500), anti-GASP antibody
(1:1000) or b-actin monoclonal antibody (1:1000) and immu-
noblotted with horseradish peroxidase (HRP)-conjugated
anti-mouse or anti-rabbit antibody. Blots were visualized with
ECL Western Blotting Substrate.
GST-fusion protein-binding assay
GST-fusion protein-binding assays were carried out as
described in Tschische et al. (2010). GST-fusion proteins were
expressed in Escherichia coli and bound to glutathione–
agarose. Fusion proteins on beads were incubated in blocking
buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 2 mM MgCl2,
0.1% Triton X-100, 5% BSA), while 35S-methionine-labelled
HA-GASP-1 was synthesized using a TNT T7 Coupled Reticu-
locyte Lysate System and subsequently incubated with the
fusion proteins in wash buffer (20 mM HEPES, pH 7.4,
100 mMNaCl, 2 mMMgCl2, 0.1%TritonX-100) for 1 h at 4°C.
Probes were washed and resolved on a SDS/PAGE. Gels were
stained with PAGEblue, dried and exposed to X-ray films.
Lentivirus production and shRNA knock-down
of GASP-1
GASP-1 knockdown experiments were performed as previ-
ously described (Tschische et al., 2010; Thompson and Whis-
tler, 2011). Virus was produced in HEK293T cells and
harvested 48 h post-transfection. Knockdown of GASP-1
levels in GPR55-HEK cells was induced by infection with
lenti-shGASP-1 (shGASP-1) or lenti-shScrambled (shScr) virus
for 48 h. Enhanced green fluorescent protein (EGFP) was used
to determine successful lentivirus infection.
Biotin internalization and
protection/degradation assays
GPR55-HEK cells were infected with either shScr or shGASP-1
virus, and experiments were conducted as previously
described (Whistler et al., 2002; Tschische et al., 2010). In brief,
cells were incubated with disulphide cleavable biotin for
10 min at 4°C andwashedwith TBS (25 mMTris base, 135 mM
NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O, pH 7.4). For internal-
ization assays, cells were placed inwarmmedium for 0–45 min
in the presence of ligands (RIMor LPI) /vehicle (DMSOorH2O)
to allow receptor endocytosis. Remaining cell surface biotin
was stripped (50 mMglutathione, 75 mMNaCl) (except 100%
plates) and quenched (50 mM iodoacetamide, 1% BSA in PBS),
followed by cell lysis (0.3% Triton X-100, 150 mM NaCl,
25 mM KCl, 10 mM Tris–HCl, 1 mM CaCl2, 5 mM iodoaceta-
mide, pH 7.4, with complete protease inhibitors). Protection/
degradation assays were performed as described above. After
quench, cells were placed inwarmOpti-MEM for the indicated
time points to allow receptor degradation (except 100% and
Strip) before cell lysates were prepared. Samples of cleared
lysates were taken for control blots (anti-GASP, anti b-actin),
and the remainder were immunoprecipitated with anti-FLAG
M2 affinity matrix. Precipitates were washed, deglycosylated,
resolved by SDS-PAGE and visualized with Vectastain ABC.
Blots were quantified using IMAGEJ Software.
Recycling experiments
ShScr or shGASP-1 virus-infected GPR55-HEK cells were
grown on poly-D-lysine-coated coverslips. Living cells were
incubated with the Ca2+-sensitive anti-FLAGM1 antibody and
stimulated with agonist (RIM or LPI) /vehicle (DMSO or H2O)
for 45 min. Remaining surface receptors – except those at
0 min and 45 min time points – were stripped (0.04% PBS–
EDTA), and warm Opti-MEM was added for up to 90 min.
Cells were fixed in 3.7% formaldehyde, blocked (50 mM Tris–
HCl, pH 7.5, 1 mM CaCl2 and 3% milk) and stained with
Alexa647-conjugated IgG2b under non-permeabilizing con-
ditions. Receptors were visualized using a laser-scanning con-
focal imaging system (Zeiss LSM510).
Statistical analysis
Statistical analysis was performed using ANOVA for compari-
sons between multiple groups followed by a Bonferroni’s post
hoc test using GraphPad Prism and Mirocal Origin software. A
P-value of <0.05 was considered significant.
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Materials
Mouse M1 and M2 monoclonal antibodies, b-actin antibody,
anti-FLAG M2 affinity matrix, BSA, L-glutathione, iodoaceta-
mide, Triton X-100, poly-D-Lysine, Kodak BioMax light films,
pysophosphatidylinositol (LPI) and Tween 20 were purchased
from Sigma Aldrich (Vienna, Austria); 4–20% Tris–glycine
gels, cell culture reagents, Lipofectamine 2000, Alexa
Fluor647nm-conjugated IgG2b were from Invitrogen (Lofer,
Austria). HRP-conjugated antibodies were obtained from
Jackson Immuno Research (Dianova, Germany). Generation
of anti-GASP-1 antibodies has been previously described
(Whistler et al., 2002). Complete Protease inhibitor cocktail
tablets were from Roche (Vienna, Austria) and PNGaseF from
New England Biolabs (Frankfurt, Germany). Immobilon-P
Transfer Membrane was purchased from Millipore (Vienna,
Austria). ECL Western Blotting Substrate was from Pierce
(THP, Austria). Vectashield mounting medium and Vectastain
ABC Kit were purchased from Vector Laboratories (Szabo-
Scandic, Austria). EZ-Link Sulpho-NHS-SS-Biotin was from
Thermo Scientific (Histocom, Austria). NaOH, KCl and
CaCl2*2H2O were obtained from Merck (Vienna, Austria),
NaCl, Tris and formaldehyde were from Roth (Lactan,
Austria). TNT T7 Coupled Reticulocyte Lysate System was
purchased from Promega (Mannheim, Germany). EasyTag
[35S]-methionine was obtained from PerkinElmer (Vienna,
Austria) and PAGEBlue from Fermentas (St. Leon-Rot,
Germany). SR141716A (rimonabant, RIM) was from Sanofi-
Synthélabo Recherche (Montpellier, France). LPI was dis-
solved in H2O and SR141716A in DMSO.
Results
GPR55 interacts with GASP-1
In HEK293 cells expressing GPR55, the receptor co-
immunoprecipitated with endogenous GASP-1 (Figure 1A;
upper panel, GPR55). Many GPCRs interact with GASP-1
through their cytoplasmic tails (Heydorn et al., 2004). This
was also the case for GPR55. Specifically, a purified recombi-
nant glutathione S-transferase (GST)-fusion protein contain-
ing the last 34 carboxyl-terminal amino acids of GPR55
bound GASP-1 in vitro, similar to the C-terminus of the
d-opioid receptor (Figure 1B; upper panel, GPR55 and DOP)
(Whistler et al., 2002), which served as positive control.
Neither the control GST protein nor the carboxyl-terminus of
the m-opioid receptor (Whistler et al., 2002) significantly
bound GASP-1 (Figure 1B; upper panel, MOP and GST).
The internalization of GPR55 is not regulated
by GASP-1
In various recombinant cell lines – including HEK293, U2OS
and MCF-7 cells – GPR55 is predominantly located on the cell
surface but internalizes following agonist stimulation (Hen-
stridge et al., 2009; 2010; Kapur et al., 2009; Ford et al., 2010).
To examine whether GASP-1 affects the internalization of
GPR55, we quantified the rate of internalization using a bioti-
nylation protection assay in HEK293 cells where GASP-1
levels were knocked down with a shRNA lentivirus (Tschische
et al., 2010). This assay allows the selective monitoring of the
endocytic fate of a pool of receptors that is expressed on the
cell surface and is subsequently stimulated with agonists. In
brief, receptors that reached the cell surface of intact cells
were labelled with thio-cleavable disulphide-linked biotin
(Figure 2A and B; upper panel, 100%). Cells were then incu-
bated with agonists in warm media to allow biotinylated
receptors to internalize for up to 45 min. After this incuba-
tion step, cell surface remaining biotin was cleaved with a
membrane impermeable reducing agent, and the ‘protected’
internalized biotinylated receptor pool was immunoprecipi-
tated and detected by streptavidin overlay. The shRNA caused
efficient knockdown of GASP-1 protein expression 48 h after
infection (Figure 2B; GASP-1), while scrambled shRNA virus
(shScr) had no effect on GASP-1 levels (Figure 2A; GASP-1). In
both, shScr (Figure 2A) and shGASP-1 (Figure 2B) infected
cells, biotinylated GPR55 internalized following treatment
with either 2.5 mM rimonabant (Figure 2A and B; left panels,
RIM and 2C) or 2.5 mM LPI (Figure 2A and B; right panels, LPI
and 2C); 45 min of vehicle (DMSO, final concentration
0.025%) treatment did not lead to significant receptor inter-
nalization in the presence and absence of GASP-1, respec-
tively (Figure S2). Lysates were immunoblotted for GASP-1
and b-actin (Figure 2A and B; lower panels). GASP-1 did not
appear to affect internalization of GPR55.
Figure 1
GPR55 interacts with GASP-1 in vitro. (A) pcDNA3.1 (pcDNA) or
FLAG-GPR55 (GPR55) were immunoprecipitated with anti-FLAG
affinity matrix (IP) and immunoblotted (IB) for GASP-1 (first panel)
and receptor (second panel). Lysates were probed for GASP-1 (third
panel) and b-actin (fourth panel). (B) GST-fusion proteins containing
the c-tail (CT) of GPR55 and the d-opioid receptor (DOP) bind
[35S]-methionine-labelled recombinant GASP-1. In contrast, GASP-1
did not bind to empty beads (B), the GST-protein (GST) alone or
GST-m-opioid receptor (MOP). Total protein levels are shown below
the autoradiograph. Blots are representative of four independent
experiments.
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GASP-1 promotes the degradation of GPR55
in response to LPI and rimonabant
Since GASP-1 has been reported to specifically target GPCRs
for degradation in lysosomes after their internalization
(Moser et al., 2010), we next assessed whether GASP-1 alters
the post-endocytic targeting of GPR55. Consistent with its
ability to bind GASP-1, GPR55 was targeted to lysosomes after
internalization (Figure S1). To quantify the post-endocytic
fate of GPR55, we next monitored the stability of a pool of
endocytosed GPR55 in the presence or absence of GASP-1
using shRNA knockdown of GASP-1 and a biotin protection/
degradation assay. Biotinylated GPR55 receptors were stimu-
lated with either 2.5 mM rimonabant (Figure 3A and C; RIM)
or 2.5 mM LPI (Figure 3B and C; LPI) for 45 min to allow
receptor internalization (45′). Remaining biotin on the cell
surface was stripped, and the internalized ‘protected’ pool of
receptors was monitored for up to 180 min (Figure 3A, B and
C; +30′, +90′ and +180′). Lysate samples immunoblotted for
b-actin (Figure 3A and B; lower panels) served as controls for
protein level.
In GPR55-HEK cells infected with shGASP-1 lentivirus
(Figure 3A and B right panels, and C), biotinylated, internal-
ized GPR55 was significantly more stable than in cells
infected with the scrambled shScr lentivirus (Figure 3A and B
left panels, and C). Taken together, these results indicate that
GASP-1 plays a crucial role for the sorting of GPR55 to the
lysosomes for degradation after endocytosis.
The recycling of GPR55 is promoted in the
absence of GASP-1
In cells devoid of GASP-1, the degradation of some GPCRs is
disrupted. In some cases, receptors are recycled back to the
cell surface (Whistler et al., 2002; Enquist et al., 2007; Martini
et al., 2007; Tschische et al., 2010), while in others the recep-
tors are neither degraded nor recycled (Thompson et al.,
2007; 2010) but retained in intracellular compartments.
Hence, we next tested whether disrupting the GPR55/GASP-1
interaction facilitated recycling of GPR55.
To assess receptor recycling, GPR55-HEK cells were
infected with shScr (Figure 4A and B; upper panels) or
Figure 2
Knockdown of GASP-1 does not impair GPR55 internalization. GPR55-HEK cells were infected with either (A) shScr or (B) shGASP-1 lentivirus.
Internalization of biotinylated FLAG-GPR55 (bio-GPR55) was monitored for the indicated time points (0′, 15′, 30′ and 45′). GPR55 internalized
after stimulation with 2.5 mM RIM (left panels) or 2.5 mM LPI (right panels) in both, shScr- and shGASP-1-infected cells. The lower panels show
the corresponding lysate samples immunoblotted for GASP-1, indicating successful GASP-1 knockdown, and b-actin. (C) Bio-GPR55 bands were
normalized to b-actin, and 15 min values were set at 1. Data are means of three independent experiments  SEM.
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shGASP-1 (Figure 4A and B; lower panels) lentivirus. Surface
receptors were labelled with anti-FLAG antibody (0 min), and
cells were then stimulated with 2.5 mM rimonabant
(Figure 4A) or 2.5 mM LPI (Figure 4B) for 45 min to allow
receptor internalization (45 min). Since cells stimulated with
vehicle (DMSO or H2O, final concentration 0.025%) did not
internalize (see Figure S2), recycling could not be monitored.
Cells were stripped of the FLAG-antibody (Strip), and receptor
trafficking was monitored for up to 90 min (+30 min,
+60 min and +90 min). Cells were fixed, and any recycled
receptor was detected by a fluorescent antibody. Before
agonist stimulation, GPR55 was detected primarily on the cell
surface (Figure 4A and B, 0 min) but internalized rapidly fol-
lowing treatment with 2.5 mM rimonabant (Figure 4A,
45 min) or 2.5 mM LPI (Figure 4B, 45 min). Following the
antibody strip (Strip), no recycled receptor was detected in
shScr-infected cells treated with either rimonabant
(Figure 4A; upper panel) or LPI (Figure 4B; upper panel) even
after 90 min, consistent with the targeting of GPR55 to the
lysosome for degradation (Figure 3 and S1). In contrast,
knockdown of GASP-1 with shGASP-1 facilitated recycling of
GPR55 back to the cell surface as early as 30 min following
the strip (Figure 4A and B, lower panel, +30, +60, +90 min).
Discussion
The sorting of GPCRs after receptor activation is a highly
regulated process and includes receptor degradation or recy-
cling back to the cell surface. One regulatory mechanism to
guarantee appropriate receptor expression levels in physi-
ological conditions is that of down-regulating GPCRs via
sorting proteins, for example GASP-1, thus leading to an
attenuation of cellular signalling events (Moser et al., 2010).
This study demonstrates the importance of GASP-1 as a
cellular regulator for the post-endocytic sorting of GPR55 to
both the exogenous agonist drug rimonabant and the
endogenous ligand LPI. GPR55 binds directly to GASP-1
(Figure 1A and B), and this interaction is essential for target-
ing the receptor to the degradative pathway (Figure 3A, B
and C; shScr). Upon stimulation with the GPR55 agonists
rimonabant and LPI, GPR55 co-localizes with the lysosomal
markers LAMP1/2 in the presence of GASP-1 (Figure S1;
shScr). In the absence of GASP-1, rapid recycling of GPR55
can be observed (Figure 4A and B; shGASP-1); however, the
agonist-induced internalization of GPR55 is not altered in
the absence of GASP-1 (Figure 2B and C). Taken together,
these results implicate GASP-1 as a key player to target
GRP55 to the lysosomes/degradative pathway upon agonist
exposure.
The endogenous ligand LPI is up to a 100-fold more
potent than rimonabant in activating intracellular signalling
cascades via GPR55 (Henstridge et al., 2010). Interestingly, we
could not observe any differences regarding the internaliza-
tion and post-endocytic sorting properties of GPR55 when
the cells were stimulated with equimolar doses of the endog-
enous ligand LPI or the diarylpyrazole rimonabant. However,
these two ligands are similarly potent (i.e. only a threefold
Figure 3
Disruption of the GASP-1/GPR55 interaction inhibits the degradation of GPR55. GPR55-HEK cells were infected with shScr virus (left panels) or
shGASP-1 virus (right panels). Biotinylated GPR55 (bio-GPR55, 100%) was allowed to internalize in the presence of (A) 2.5 mM RIM or (B) 2.5 mM
LPI for 45 min (45′) before cells were stripped of surface-biotin (Strip). The degradation of GPR55 was monitored for an additional 180 min (+30,
+90 and +180). GPR55 degradation was observed in shScr (A and B; left panel, C), but not in shGASP-1 (A and B; right panel; C) infected cells.
(C) Quantification of biotinylation assays in (A) and (B). Biotinylated GPR55 bands from shScr or shGASP-1 infected cells were normalized to b-actin
and 45 min values were set at 100%. Data are means of three independent experiments  SEM, *P < 0.05, **P < 0.01.
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difference between LPI and rimonabant) in recruiting
b-arrestin to GPR55 (Kapur et al., 2009).
For centuries, cannabinoids have played an important
role in medicine due to their psychoactive, analgesic and
anti-inflammatory properties. Since then, many natural and
synthetic compounds, which have the ability to bind CB1
and CB2 receptors, have been discovered. Recently, the GPCR
GPR55 was ‘de-orphanized’ and characterized as a novel,
non-CB1/CB2 cannabinoid receptor. Rimonabant – developed
as a CB1 receptor inverse agonist/antagonist – has recently
attracted significant attention, since it was marketed for
weight loss and smoking cessation. Due to adverse side
effects, including the development of anxiety and depression
in patients (Christensen et al., 2007), rimonabant was with-
drawn from the market. Recently, rimonabant has been
shown to be not only an antagonist/inverse agonist at the
CB1 receptor but also an agonist at GPR55 (Ryberg et al., 2007;
Kapur et al., 2009; Henstridge et al., 2010), a potential off
target effect that could be contributing to the adverse events.
Although much higher concentrations of rimonabant than
typically used for CB1 receptor antagonism (5–15 nM) (see
Pertwee et al., 2010) are required to elicit an effect on GPR55
(Ryberg et al., 2007; Henstridge et al., 2010), a role for GPR55
activation needs to be considered where micromolar concen-
trations of rimonabant are present (i.e. during long-term
treatment and/or accumulation in fatty tissues) such as the
brain.
Intriguingly, the side effects of rimonabant were pervasive
only after prolonged drug use, suggesting that they were not
a consequence of acute activation/inhibition of GPR55/CB1
receptors, but could be a consequence of prolonged agonist
exposure. For instance, a prominent example of how pro-
longed agonist stimulation of a GPCR results in the develop-
ment of adverse effects both in vitro (Finn andWhistler, 2001)
and in vivo (Kim et al., 2008) is that of the m-opioid receptor in
response to chronic morphine. As outlined in the introduc-
tion, prolonged exposure to agonists also results in the GASP-
1-mediated down-regulation of D2 (Bartlett et al., 2005; Boeuf
Figure 4
Recycling of GPR55 is enhanced in the absence of GASP-1. shScr (upper panels) or shGASP-1 (lower panels) infected GPR55-HEK cells were
incubated with anti-FLAG antibody for 45 min (0 min) to label surface receptors. Cells were incubated with (A) 2.5 mM RIM or (B) 2.5 mM LPI for
45 min (45 min) to allow internalization and then stripped of surface antibody (Strip). Cells were incubated in warm medium for up to 90 min
(+30 min, +60 min, +90 min) to allow degradation. In contrast to shScr-infected GPR55-HEK cells (A and B; upper panels), GPR55 recycled in
shGASP-1-infected cells (A and B; lower panels). Insets indicate EGFP-shRNA-virus expression. Scale bar = 20 mm.
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et al., 2009; Thompson et al., 2010) and CB1 receptors
(Martini et al., 2007; 2010; Tappe-Theodor et al., 2007) in vitro
and in vivo and dramatically changes the behavioural
responses to these drugs.
Here we used a model HEK293 cell culture system exog-
enously expressing FLAG-tagged GPR55 and showed that,
likewise, GPR55 is down-regulated after exposure to rimona-
bant within 3 h, and that this process is dependent on
GASP-1 (see Figure 3A). It is tempting to speculate that pro-
longed exposure to rimonabant would cause a down-
regulation of GPR55 in vivo and thereby may contribute to
the adverse side effects of this drug. However, in light of the
ambidextrous role of rimonabant – i.e. being an antagonist of
CB1 and an agonist of GPR55 receptors – the relative effect of
rimonabant on GPR55 and CB1 receptors after prolonged use,
and ultimately the adverse effects of this drug, have yet to be
verified in vivo.
Recently, GPR55 has been shown to be highly expressed
in malignant human tumours (Andradas et al., 2011) and
cancer cell lines (Ford et al., 2010; Pineiro et al., 2011), and its
expression is correlated to tumour aggressiveness (Andradas
et al., 2011). Hence, by identifying GASP-1 as a key regulator
of the trafficking and, by extension, functional expression of
GPR55, we may be one step closer to gaining a better under-
standing of this receptor in response to cannabinoid drugs
and its significance in pathogenesis.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 GASP-1 promotes the sorting of GPR55 to lysos-
omes. (A) GPR55-HEK cells infected with shScr lentivirus were
fed anti-FLAG antibody and were either left untreated (0 min)
or treated with 2.5 mM of RIM or LPI for 30 or 90 min. Recep-
tors (green) were analysed for co-localization with the lyso-
somal markers LAMP1/2 (red) (B) GPR55-HEK cells were
infected with shGASP-1 and treated as in panel A. No
co-localization was observed for GPR55 (green) and LAMP1/2
(red) in shGASP-1 cells, but receptors were predominantly
found on – or in vesicles close to – the cell surface. Inserts in
FLAG-GPR55 panels indicate EGFP-shRNA-virus expression.
Scale bars = 10 mM.
Figure S1 GPR55 does not internalize in response to vehicle.
GPR55-HEK cells were infected with shScr (left panel) or
shGASP-1 (right panel) lentivirus. In the presence and
absence of GASP-1 biotinylated GPR55 (bio-GPR55, 100%)
internalized in response to 45 min of RIM, but not vehicle
(DMSO), stimulation.
Table S1 Endogenous GPR55 and GASP-1 expression in dif-
ferent cell lines. Undifferentiated (uHL60), differentiated
(dHL60) human promyelocytic leukemia cells (HL60) and
several colon cancer cell lines (HT-29, CaCo-2, DLD-1,
SW480, SW620) were screened for endogenous GPR55 and
GASP-1 expression by using either (i) real-time PCR or (ii)
Western Blot techniques. Total RNA was isolated using
RNeasy Mini Kit (Qiagen, Hilden, Germany), and cDNA was
obtained with High Capacity cDNA Transcriptase Kit (Applied
Biosystems, Vienna, Austria). Real-time PCR was performed
by using Fast SYBR Green PCR Master Mix (Applied Biosys-
tems). GPR55 protein expression was determined by Western
Blot analysis using a specific GPR55 antibody (Cayman, VWR
Scientific, Vienna, Austria)
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